DHR Stock Recent News
DHR LATEST HEADLINES
Danaher (DHR) benefits from strength in the clinical diagnostics business, Abcam buyout and pro-investor policies. However, softness in its Instrument unit is concerning.
Market corrections happen under almost every president, and stock performance is not tied to political parties. Currently, inflation remains the key driver of market movements. Focus on undervalued opportunities in any market condition. Consistent investment in solid stocks is more effective than trying to time the market. Three key stocks in our portfolios demonstrate resilience and growth potential, offering a mix of dividend growth and value despite current market challenges.
Investors looking for stocks in the Diversified Operations sector might want to consider either Hitachi Ltd. (HTHIY) or Danaher (DHR).
The Investment Committee give you their top stocks to watch for the second half.
BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the DxI 9000 Immunoassay Analyzer* was honored during Premier, Inc.'s annual supplier Innovation Celebration at its 2024 Breakthroughs Conference and Exhibition.
Danaher's (DHR) second-quarter earnings and revenues surpass estimates. However, the company's performance reflects a decrease in core sales in the Biotechnology segment.
Danaher Corp. (DHR) beat analysts' expectations on the top and bottom lines with its second-quarter results, sending shares higher in intraday trading Tuesday.
The pandemic has created a lot of noise around Danaher's revenue growth, but the dust looks set to settle in 2024. Core revenue and margins were better than expected in the second quarter.
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher Corporation (NYSE:DHR ) Q2 2024 Earnings Conference Call July 23, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer M. Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Jack Meehan - Nephron Research Rachel Vatnsdal - J.P.